Publications
La recherche au service
de nos patients
Nos activités de recherche ont permis aux chercheurs de l’ICAP de présenter les résultats de leurs travaux dans des revues référencés au niveau national mais aussi international.
Vous trouverez ci-dessous les principales publications des dernières années.
PUBLICATIONS INDEXÉES DANS PUBMED
- Levy, A ; Adebahr, S ; Hurkmans, C ; Ahmed, M ; Ahmad, S ; Guckenberger, M & al , Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results., J Thorac Oncol, 2024, ,
- Borel, C ; Sun, XS ; Coutte, A ; Bera, G ; Sire, C ; Zanetta, S & al , Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial., Radiother Oncol, 2024, 197, 110329
- Botsen, D ; Chabaud, S ; Perrier, H ; Ammarguellat, H ; Jestin-Le-Tallec, V ; Olesinski, J & al , Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial., Dig Liver Dis, 2024, ,
- Petit, T ; Hajjaji, N ; Antoine, EC ; Benderra, MA ; Gozy, M ; Foa, C & al , Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France., Cancer Med, 2024, 13, e7168
- Penault-Llorca, F ; Dalenc, F ; Chabaud, S ; Cottu, P ; Allouache, D ; Cameron, D & al , Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial., ESMO Open, 2024, 9, 103443
- Basse, C ; Khalifa, J ; Thillays, F ; Le Pechoux, C ; Maury, JM ; Bonte, PE & al , Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma-a French DELPHI Consensus Initiative., J Thorac Oncol, 2024, 19, 1095-1107
- Kim, S ; Ghiringhelli, F ; de la Fouchardière, C ; Evesque, L ; Smith, D ; Badet, N & al , Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study., Lancet Oncol, 2024, 25, 518-528
- Varnier, R ; Toullec, C ; Philonenko, S ; Dupré, A ; Artru, P ; Hafliger, E & al , Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study., Dig Liver Dis, 2024, ,
- Franzoi, MA ; Aupomerol, M ; Havas, J ; Soldato, D ; Lambertini, M ; Massarotti, C & al , Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes., ESMO Open, 2024, 9, 102236
- Rossi, JF ; Frayssinet, P ; Matciyak, M ; Tupitsyn, N , Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer., Cancer Biol Med, 2024, 20, 1021-34
- Desroys du Roure, P ; Lajoie, L ; Mallavialle, A ; Alcaraz, LB ; Mansouri, H ; Fenou, L & al , A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer., J Immunother Cancer, 2024, 12,
- Delbaere, A ; Younes, T ; Khamphan, C ; Vieillevigne, L , Experimental validation of absorbed dose-to-medium calculation algorithms in heterogeneous media., Phys Med Biol, 2024, 69,
- Bourbonne, V ; Lévy, A ; Khalifa, J ; Antoni, D ; Blais, E ; Darréon, J & al , Radiotherapy in the management of lung oligometastases., Cancer Radiother, 2024, 28, 36-48
- Vaugier, L ; Martin-Mervoyer, E ; Ah-Thiane, L ; Langé, M ; Ollivier, L ; Perennec, T & al , How to contour the different heart subregions for future deep-learning modeling of the heart: A practical pictorial proposal for radiation oncologists., Clin Transl Radiat Oncol, 2024, 45, 100718
- Naessens, C ; Chamois, J ; Supiot, S ; Faivre, JC ; Arnaud, A ; Thureau, S , Stereotactic body radiation therapy for bone oligometastases., Cancer Radiother, 2024, 28, 111-118
- Mineur, L ; Plat, F ; Desseigne, F ; Deplanque, G ; Belkacemi, M ; Moureau-Zabotto, L & al , NESC Multicenter Phase II Trial in the Preoperative Treatment of Gastric Adenocarcinoma with Chemotherapy (Docetaxel-Cisplatin-5FU+Lenograstim) Followed by Chemoradiation Based 5FU and Oxaliplatin and Surgery., Cancer Res Treat, 2024, 56, 580-589
- Khalifa, J ; Lévy, A ; Sauvage, LM ; Thureau, S ; Darréon, J ; Le Péchoux, C & al , Radiotherapy in the management of synchronous metastatic lung cancer., Cancer Radiother, 2024, 28, 22-35
- Besse, B ; Felip, E ; Garcia Campelo, R ; Cobo, M ; Mascaux, C ; Madroszyk, A & al , Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1., Ann Oncol, 2023, 34, 920-933
- Campos-Mora, M ; Jacot, W ; Garcin, G ; Depondt, ML ; Constantinides, M ; Alexia, C & al , NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells., Front Immunol, 2023, 14, 1199594
- Taïeb, J ; Bouche, O ; André, T ; Le Malicot, K ; Laurent-Puig, P ; Bez, J & al , Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial., JAMA Oncol, 2023, 9, 1356-1363
- Delaby, N ; Barateau, A ; Chiavassa, S ; Biston, MC ; Chartier, P ; Graulières, E & al , Practical and technical key challenges in head and neck adaptive radiotherapy: The GORTEC point of view., Phys Med, 2023, 109, 102568
- Rassy, E ; Filleron, T ; Viansone, A ; Lacroix-Triki, M ; Rivera, S ; Desmoulins, I & al , Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials., Breast Cancer Res Treat, 2023, 199, 371-379
- Féray, C ; Campion, L ; Mathurin, P ; Archambreaud, I ; Mirabel, X ; Bronowicki, JP & al , TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial., JHEP Rep, 2023, 5, 100689
- Bergen, ES ; Pilla, L ; Auclin, E ; Ilhan-Mutlu, A ; Prager, GW ; Pietrantonio, F & al , Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study., Gastric Cancer, 2023, 26, 425-437
- Blanc-Durand, F ; Yaniz-Galende, E ; Llop-Guevara, A ; Genestie, C ; Serra, V ; Herencia-Ropero, A & al , A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer., Gynecol Oncol, 2023, 171, 106-113
- Walter, T ; Lievre, A ; Coriat, R ; Malka, D ; Elhajbi, F ; Di Fiore, F & al , Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial., Lancet Oncol, 2023, 24, 297-306
- Debourdeau, P ; Flori, N ; Vazquez, L ; Triolaire, V ; Charpy, F ; Debourdeau, E & al , Non-compliance with end-of-life parenteral nutrition prescription recommendations: retrospective study of 1,260 cancer patients., Ann Palliat Med, 2022, 11, 3417-3425
- Bidard, FC ; Hardy-Bessard, AC ; Dalenc, F ; Bachelot, T ; Pierga, JY ; de la Motte Rouge, T & al , Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial., Lancet Oncol, 2022, 23, 1367-1377
- Adhoute, X ; De Matharel, M ; Mineur, L ; Pénaranda, G ; Ouizeman, D ; Toullec, C & al , Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching., World J Gastrointest Oncol, 2022, 14, 1510-1527
- Andre, F ; Filleron, T ; Kamal, M ; Mosele, F ; Arnedos, M ; Dalenc, F & al , Genomics to select treatment for patients with metastatic breast cancer., Nature, 2022, 610, 343-348
- Delabrusse, B ; Le Meur, B ; Vazquez, L ; Boustany, R ; Serin, D , [Cancers induced by occupational exposure: What progress has been made?]., Bull Cancer, 2022, 109, 1029-1039
- Rossi, JF ; Chiang, HC ; Lu, ZY ; Levon, K ; van Rhee, F ; Kanhai, K & al , Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling., Front Immunol, 2022, 13, 919489
- de Nonneville, A ; Salas, S ; Bertucci, F ; Sobinoff, AP ; Adélaïde, J ; Guille, A & al , TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT., EMBO Mol Med, 2022, 14, e15859
- Biston, MC ; Meyer, P ; Ferrer, L ; Marchesi, V ; Khamphan, C ; Bonniaud, G & al , Highlights from the 59th scientific congress of the French Society of Medical Physics., Phys Med, 2022, 101, 18-19
- Coënon, L ; Villalba, M , From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement., Front Immunol, 2022, 13, 913215
- Vo, DN ; Leventoux, N ; Campos-Mora, M ; Gimenez, S ; Corbeau, P ; Villalba, M , NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1., Vaccines (Basel), 2022, 10,
- Bachelot, T ; Cottu, P ; Chabaud, S ; Dalenc, F ; Allouache, D ; Delaloge, S & al , Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer., J Clin Oncol, 2022, 40, 3699-3708
- Khan, AUH ; Salehi, H ; Alexia, C ; Valdivielso, JM ; Bozic, M ; Lopez-Mejia, IC & al , Glucose Starvation or Pyruvate Dehydrogenase Activation Induce a Broad, ERK5-Mediated, Metabolic Remodeling Leading to Fatty Acid Oxidation., Cells, 2022, 11,
- Heudel, P ; Frenel, JS ; Dalban, C ; Bazan, F ; Joly, F ; Arnaud, A & al , Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial., JAMA Oncol, 2022, 8, 1001-1009
- Alma, S ; Eloi, D ; Léa, V ; Julie, C ; Valérie, M ; Pierre, G & al , Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors., J Thromb Thrombolysis, 2022, 54, 287-294
- Efimov, SV ; Matsiyeuskaya, NV ; Boytsova, OV ; Akhieva, LY ; Kuntsevich, EV ; Troshina, AA & al , Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19., Drugs Context, 2022, 11,
- Basile, D ; Broudin, C ; Emile, JF ; Falcoz, A ; Pagès, F ; Mineur, L & al , Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)., Ann Oncol, 2022, 33, 628-637
- Delbaere, A ; Younes, T ; Simon, L ; Khamphan, C ; Vieillevigne, L , Field output correction factors and electron fluence perturbation of the microSilicon and microSilicon X detectors., Phys Med Biol, 2022, 67,
- Fallet, V ; Rouby, P ; Ahle, G ; Arrondeau, J ; Naltet, C ; Duflot-Boukobza, A & al , [Central nervous system disorders on lorlatinib: How to detect and manage in practice?]., Bull Cancer, 2022, 109, 477-490
- Belkahla, S ; Brualla, JM ; Fayd » »herbe de Maudave, A ; Falvo, P ; Allende-Vega, N ; Constantinides, M & al , The metabolism of cells regulates their sensitivity to NK cells depending on p53 status., Sci Rep, 2022, 12, 3234
- Reina-Ortiz, C ; Giraldos, D ; Azaceta, G ; Palomera, L ; Marzo, I ; Naval, J & al , Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma., Cells, 2022, 11,
- Voute, M ; Riant, T ; Amodéo, JM ; André, G ; Barmaki, M ; Collard, O & al , Ketamine in chronic pain: A Delphi survey., Eur J Pain, 2022, 26, 873-887
- Torres-Lacomba, M ; Prieto-Gómez, V ; Arranz-Martín, B ; Ferrandez, JC ; Yuste-Sánchez, MJ ; Navarro-Brazález, B & al , Manual Lymph Drainage With Progressive Arm Exercises for Axillary Web Syndrome After Breast Cancer Surgery: A Randomized Controlled Trial., Phys Ther, 2022, 102,
- Allende-Vega, N ; Marco Brualla, J ; Falvo, P ; Alexia, C ; Constantinides, M ; de Maudave, AF & al , Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)., Sci Rep, 2022, 12, 1341
- Pernot, S ; Pellerin, O ; Mineur, L ; Monterymard, C ; Smith, D ; Lapuyade, B & al , Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49., Dig Liver Dis, 2022, 54, 324-330
- Trémolières, P ; Gonzalez-Moya, A ; Paumier, A ; Mege, M ; Blanchecotte, J ; Theotime, C & al , Lung stereotactic body radiation therapy: personalized PTV margins according to tumor location and number of four-dimensional CT scans., Radiat Oncol, 2022, 17, 5
- Ychou, M ; Rivoire, M ; Thezenas, S ; Guimbaud, R ; Ghiringhelli, F ; Mercier-Blas, A & al , Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial., Br J Cancer, 2022, 126, 1264-1270
- Khalifa, J ; Lerouge, D ; Le Péchoux, C ; Pourel, N ; Darréon, J ; Mornex, F & al , Radiotherapy for primary lung cancer., Cancer Radiother, 2022, 26, 231-243
- Pourel, N ; Meyrieux, C ; Lisbona, A , Quality/risk management system in radiotherapy: Changes afoot., Cancer Radiother, 2022, 26, 14-19
- Molinier, O ; Besse, B ; Barlesi, F ; Audigier-Valette, C ; Friard, S ; Monnet, I & al , IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer., ESMO Open, 2022, 7, 100353
- Le Pechoux, C ; Pourel, N ; Barlesi, F ; Lerouge, D ; Antoni, D ; Lamezec, B & al , Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial., Lancet Oncol, 2022, 23, 104-114
- Fayd » »herbe De Maudave, A ; Leconet, W ; Toupet, K ; Constantinides, M ; Bossis, G ; de Toledo, M & al , Intra-articular delivery of full-length antibodies through the use of an in situ forming depot., J Control Release, 2022, 341, 578-590
- Lavit, E ; Aldea, M ; Piperno-Neumann, S ; Firmin, N ; Italiano, A ; Isambert, N & al , Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group., Int J Cancer, 2022, 150, 645-653
- Borras, JM ; Corral, J ; Aggarwal, A ; Audisio, R ; Espinas, JA ; Figueras, J & al , Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink., Eur J Surg Oncol, 2022, 48, 967-977
- Borras, JM ; Corral, J ; Aggarwal, A ; Audisio, R ; Espinas, JA ; Figueras, J & al , Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink., Radiother Oncol, 2022, 169, 114-123
- Leleu, T ; Bastit, V ; Doré, M ; Kammerer, E ; Florescu, C ; Alfonsi, M & al , Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance., Cancer Radiother, 2022, 26, 440-444
- Guigay, J ; Chamorey, E ; Lefebvre, G ; Rotarski, M ; Wagner, JP ; Blot, E & al , Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT., Cancer Rep (Hoboken), 2022, 5, e1467
- Mékidèche, T ; Armoiry, X ; Sautet, P ; Dussart, C ; Mandy, B , [Economic evaluation of porous metal cones in total knee arthroplasty]., Ann Pharm Fr, 2022, 80, 81-88
- Girard, P ; Laporte, S ; Chapelle, C ; Falvo, N ; Falchero, L ; Cloarec, N & al , Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study., Thromb Haemost, 2022, 122, 151-157
- Masson, I ; Bellanger, M ; Perrocheau, G ; Mahé, MA ; Azria, D ; Pommier, P & al , Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study., Front Oncol, 2021, 11, 781121
- Gonzalez-Moya, A ; Supiot, S ; Seegers, V ; Lizée, T ; Legouté, F ; Perennec, T & al , Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients., Front Oncol, 2021, 11, 787347
- Pujalte Martin, M ; Borchiellini, D ; Thamphya, B ; Guillot, A ; Paoli, JB ; Besson, D & al , TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer., Clin Genitourin Cancer, 2021, 19, 501-509
- Culine, S ; Harter, V ; Gravis, G ; Fléchon, A ; Chevreau, C ; Mahammedi, H & al , Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial., Clin Genitourin Cancer, 2021, 19, 554-562
- Caputo, SM ; Golmard, L ; Léone, M ; Damiola, F ; Guillaud-Bataille, M ; Revillion, F & al , Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach., Am J Hum Genet, 2021, 108, 1907-1923
- Bizot, A ; Karimi, M ; Rassy, E ; Heudel, PE ; Levy, C ; Vanlemmens, L & al , Multicenter evaluation of breast cancer patients » satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic., Br J Cancer, 2021, 125, 1486-1493
- Bourgier, C ; Cowen, D ; Castan, F ; Lemanski, C ; Gourgou, S ; Rivera, S & al , Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ., Radiother Oncol, 2021, 164, 57-65
- Klinghammer, K ; Fayette, J ; Kawecki, A ; Dietz, A ; Schafhausen, P ; Folprecht, G & al , A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study., ESMO Open, 2021, 6, 100242
- Bikdeli, B ; Jiménez, D ; Del Toro, J ; Piazza, G ; Rivas, A ; Fernández-Reyes, JL & al , Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism., J Am Heart Assoc, 2021, 10, e021467
- Lopes, RD ; Higano, CS ; Slovin, SF ; Nelson, AJ ; Bigelow, R ; Sørensen, PS & al , Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial., Circulation, 2021, 144, 1295-1307
- Debourdeau, P ; Lamblin, A ; Debourdeau, T ; Marcy, PY ; Vazquez, L , Venous thromboembolism associated with central venous catheters in patients with cancer: From pathophysiology to thromboprophylaxis, areas for future studies., J Thromb Haemost, 2021, 19, 2659-2673
- Lesueur, F ; Eon-Marchais, S ; Bonnet-Boissinot, S ; Beauvallet, J ; Dondon, MG ; Golmard, L & al , TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing., Cancers (Basel), 2021, 13,
- Ribeiro Guerra, M ; Coignard, J ; Eon-Marchais, S ; Dondon, MG ; Le Gal, D ; Beauvallet, J & al , Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation., Breast Cancer Res, 2021, 23, 79
- Jiao, Y ; Lesueur, F ; Azencott, CA ; Laurent, M ; Mebirouk, N ; Laborde, L & al , A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers., BMC Med Res Methodol, 2021, 21, 155
- Miles, D ; Gligorov, J ; André, F ; Cameron, D ; Schneeweiss, A ; Barrios, C & al , Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer., Ann Oncol, 2021, 32, 994-1004
- Zelek, L ; Debourdeau, P ; Bourgeois, H ; Wagner, JP ; Brocard, F ; Lefeuvre-Plesse, C & al , A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy., Oncologist, 2021, 26, e1870-e1879
- Gallois, C ; Emile, JF ; Kim, S ; Monterymard, C ; Gilabert, M ; Bez, J & al , Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial., Dig Liver Dis, 2021, 53, 1254-1259
- Mazard, T ; Cayrefourcq, L ; Perriard, F ; Senellart, H ; Linot, B ; de la Fouchardière, C & al , Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study., Cancers (Basel), 2021, 13,
- Meyer, P ; Biston, MC ; Khamphan, C ; Marghani, T ; Mazurier, J ; Bodez, V & al , Automation in radiotherapy treatment planning: Examples of use in clinical practice and future trends for a complete automated workflow., Cancer Radiother, 2021, 25, 617-622
- Hamadou, WS ; Mani, R ; Bouali, N ; Besbes, S ; Bourdon, V ; El Abed, R & al , Mutational analysis of apoptotic genes in familial aggregation of hematological malignancies., Bull Cancer, 2021, 108, 798-805
- Taieb, J ; Taly, V ; Henriques, J ; Bourreau, C ; Mineur, L ; Bennouna, J & al , Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial., Clin Cancer Res, 2021, 27, 5638-5646
- Tutt, ANJ ; Garber, JE ; Kaufman, B ; Viale, G ; Fumagalli, D ; Rastogi, P & al , Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer., N Engl J Med, 2021, 384, 2394-2405
- Chevalier, T ; Daste, A ; Saada-Bouzid, E ; Loundou, A ; Peyraud, F ; Lambert, T & al , Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME., Cancer Med, 2021, 10, 3952-3963
- Borjas Howard, J ; Ruiz-Sada, P ; de Leeuw, K ; López-Jiménez, L ; Font, C ; Marchena, PJ & al , Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry., Br J Haematol, 2021, 194, 195-199
- Gonzalez-Moya, A ; Dufreneix, S ; Ouyessad, N ; Guillerminet, C ; Autret, D , Evaluation of a commercial synthetic computed tomography generation solution for magnetic resonance imaging-only radiotherapy., J Appl Clin Med Phys, 2021, 22, 191-197
- Barthélémy, P ; Rioux-Leclercq, N ; Thibault, C ; Saldana, C ; Borchiellini, D ; Chevreau, C & al , Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data., Cancer Treat Rev, 2021, 97, 102191
- Charles, C ; Vaz Luis, I ; Chiesa, S ; Boiron, C ; Bourgier, C ; Cavalcanti, A & al , [An updated synthesis of the international recommendations about the use of non-pharmacological interventions in the treatment of fatigue]., Bull Cancer, 2021, 108, 740-750
- Hernandez, V ; Saez, J ; Angerud, A ; Cayez, R ; Khamphan, C ; Nguyen, D & al , Dosimetric leaf gap and leaf trailing effect in a double-stacked multileaf collimator., Med Phys, 2021, 48, 3413-3424
- Di Meglio, A ; Gbenou, AS ; Martin, E ; Pistilli, B ; Ligibel, JA ; Crane, TE & al , Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements., Cancer, 2021, 127, 2774-2787
- Petit, C ; Lacas, B ; Pignon, JP ; Le, QT ; Grégoire, V ; Grau, C & al , Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis., Lancet Oncol, 2021, 22, 727-736
- Gravis, G ; Autret, A ; Guibert-Broudic, M ; Dubergé, T ; Zemmour, C ; Carrier, P & al , Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET., Clin Genitourin Cancer, 2021, 19, 346-353
- Mékidèche, T ; Curti, C ; Lamy, E ; Jean, C ; Peres, PB ; Vanelle, P , Compounding and quality control of two pediatric topiramate pharmaceutical preparations., Pharmazie, 2021, 76, 150-154
- Aparicio, T ; Cozic, N ; de la Fouchardière, C ; Meriaux, E ; Plaza, J ; Mineur, L & al , The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program., Target Oncol, 2021, 16, 381-388
- Efimov, SV ; Matsiyeuskaya, NV ; Boytsova, OV ; Akhieva, LY ; Kvasova, EI ; Harrison, F & al , The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study., Drugs Context, 2021, 10,
- Vazquez, L ; Arnaud, A ; Grenier, J ; Debourdeau, P , [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?], Bull Cancer, 2021, 108, 544-552
- Oziel-Taieb, S ; Zemmour, C ; Raoul, JL ; Mineur, L ; Poizat, F ; Charrier, N & al , Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors., Anticancer Res, 2021, 41, 2071-2078
- Kelly, RJ ; Ajani, JA ; Kuzdzal, J ; Zander, T ; Van Cutsem, E ; Piessen, G & al , Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer., N Engl J Med, 2021, 384, 1191-1203
- Rossi, JF ; Lu, ZY ; Massart, C ; Levon, K , Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer., Front Immunol, 2021, 12, 595722
- Guigay, J ; Aupérin, A ; Fayette, J ; Saada-Bouzid, E ; Lafond, C ; Taberna, M & al , Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial., Lancet Oncol, 2021, 22, 463-475
- Rouanet, P ; Rivoire, M ; Gourgou, S ; Lelong, B ; Rullier, E ; Jafari, M & al , Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial., Br J Surg, 2021, 108, 10-13
- Coignard, J ; Lush, M ; Beesley, J ; O » »Mara, TA ; Dennis, J ; Tyrer, JP & al , A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers., Nat Commun, 2021, 12, 1078
- Karoui, M ; Gallois, C ; Piessen, G ; Legoux, JL ; Barbier, E ; De Chaisemartin, C & al , Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years » follow-up results of the PRODIGE 22 phase II randomized multicentre trial., Colorectal Dis, 2021, 23, 1357-1369
- Gomes, F ; Faivre-Finn, C ; Mistry, H ; Bezjak, A ; Pourel, N ; Fournel, P & al , Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer – Secondary analysis of the randomised phase 3 CONVERT trial., Lung Cancer, 2021, 153, 165-170
- Lacas, B ; Carmel, A ; Landais, C ; Wong, SJ ; Licitra, L ; Tobias, JS & al , Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group., Radiother Oncol, 2021, 156, 281-293
- Schrijver, LH ; Antoniou, AC ; Olsson, H ; Mooij, TM ; Roos-Blom, MJ ; Azarang, L & al , Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study., Am J Obstet Gynecol, 2021, 225, 51.e1-51.e17
- Bachelot, T ; Filleron, T ; Bieche, I ; Arnedos, M ; Campone, M ; Dalenc, F & al , Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial., Nat Med, 2021, 27, 250-255
- Assenat, E ; Mineur, L ; Mollevi, C ; Lopez-Crapez, E ; Lombard-Bohas, C ; Samalin, E & al , Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)., Int J Cancer, 2021, 148, 682-691
- Lonjou, C ; Eon-Marchais, S ; Truong, T ; Dondon, MG ; Karimi, M ; Jiao, Y & al , Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility., Int J Cancer, 2021, 148, 1895-1909
- Taïeb, J ; André, T ; El Hajbi, F ; Barbier, E ; Toullec, C ; Kim, S & al , Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial., Dig Liver Dis, 2021, 53, 318-323
- Goldman, JW ; Dvorkin, M ; Chen, Y ; Reinmuth, N ; Hotta, K ; Trukhin, D & al , Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial., Lancet Oncol, 2021, 22, 51-65
- Expósito-Ruiz, M ; Arcelus, JI ; Caprini, JA ; López-Espada, C ; Bura-Riviere, A ; Amado, C & al , Timing and characteristics of venous thromboembolism after noncancer surgery., J Vasc Surg Venous Lymphat Disord, 2021, 9, 859-867.e2
- Aide, N ; Fauchille, P ; Coquan, E ; Ferron, G ; Combe, P ; Meunier, J & al , Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer., Eur J Nucl Med Mol Imaging, 2021, 48, 1998-2008
- Arnaud, A ; Grenier, J ; Boustany, R ; Kirscher, S ; Mege, A ; de Rauglaudre, G & al , Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer., Support Care Cancer, 2021, 29, 3735-3742
- Blondon, M ; Jimenez, D ; Robert-Ebadi, H ; Del Toro, J ; Lopez-Jimenez, L ; Falga, C & al , Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study., J Thromb Haemost, 2021, 19, 408-416
- Rouanet, P ; Rivoire, M ; Gourgou, S ; Lelong, B ; Rullier, E ; Jafari, M & al , Sphincter-saving surgery for ultra-low rectal carcinoma initially indicated for abdominoperineal resection: Is it safe on a long-term follow-up?, J Surg Oncol, 2021, 123, 299-310
- Guirimand, F ; Bouleuc, C ; Sahut d » »Izarn, M ; Martel-Samb, P ; Guy-Coichard, C ; Picard, S & al , Development and Validation of the QUALI-PALLI-FAM Questionnaire for Assessing Relatives » Perception of Quality of Inpatient Palliative Care: A Prospective Cross-Sectional Survey., J Pain Symptom Manage, 2021, 61, 991-1001.e3
- Letestu, R ; Dahmani, A ; Boubaya, M ; Baseggio, L ; Campos, L ; Chatelain, B & al , Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia., Leukemia, 2021, 35, 1597-1609
- Mineur, L ; François, E ; Plassot, C ; Phelip, JM ; Miglianico, L ; Dourthe, LM & al , PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer., PLoS One, 2020, 15, e0243997
- Bertucci, A ; Bertucci, F ; Zemmour, C ; Lerebours, F ; Pierga, JY ; Levy, C & al , PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer., Front Oncol, 2020, 10, 575978
- Arnaud, A ; Grenier, J ; Boustany, R ; Kirscher, S ; Mege, A ; de Rauglaudre, G & al , Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer., Support Care Cancer, 2020, ,
- Hardy-Bessard, AC ; Brocard, F ; Clatot, F ; Lortholary, A ; You, B ; Grenier, J & al , First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study., Breast, 2020, 54, 256-263
- Debourdeau, P ; Belkacémi, M ; Economos, G ; Assénat, E ; Hilgers, W ; Coussirou, J & al , Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancer., BMJ Support Palliat Care, 2020, ,
- Lièvre, A ; Turpin, A ; Ray-Coquard, I ; Le Malicot, K ; Thariat, J ; Ahle, G & al , Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)., Eur J Cancer, 2020, 141, 62-81
- Blondon, M ; Jimenez, D ; Robert-Ebadi, H ; Del Toro, J ; Lopez-Jimenez, L ; Falga, C & al , Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study., J Thromb Haemost, 2020, ,
- Lamy, PJ ; van der Leest, P ; Lozano, N ; Becht, C ; Duboeuf, F ; Groen, HJM & al , Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study., Cancers (Basel), 2020, 12,
- Chibaudel, B ; Henriques, J ; Rakez, M ; Brenner, B ; Kim, TW ; Martinez-Villacampa, M & al , Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial., JAMA Netw Open, 2020, 3, e2020425
- Jacot, W ; Arnaud, A ; Jarlier, M ; Lefeuvre-Plesse, C ; Dalivoust, P ; Senesse, P & al , Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial., Nutrients, 2020, 12,
- Guirimand, F ; Bouleuc, C ; Sahut d » »Izarn, M ; Martel-Samb, P ; Guy-Coichard, C ; Picard, S & al , Development and Validation of the QUALI-PALLI-FAM Questionnaire for Assessing Relatives » Perception of Quality of Inpatient Palliative Care: A Prospective Cross-Sectional Survey., J Pain Symptom Manage, 2020, ,
- Letestu, R ; Dahmani, A ; Boubaya, M ; Baseggio, L ; Campos, L ; Chatelain, B & al , Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia., Leukemia, 2020, ,
- Thureau, S ; Briens, A ; Decazes, P ; Castelli, J ; Barateau, A ; Garcia, R & al , PET and MRI guided adaptive radiotherapy: Rational, feasibility and benefit., Cancer Radiother, 2020, 24, 635-644
- Mège, A ; Biau, J ; Meyer, E ; Allouache, N ; Guigo, M ; Servagi Vernat, S , [Clinical trials that have changed our practices 2010-2020]., Cancer Radiother, 2020, 24, 612-622
- Bachet, JB ; Blons, H ; Hammel, P ; Hariry, IE ; Portales, F ; Mineur, L & al , Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma., Clin Cancer Res, 2020, 26, 5208-5216
- Gobbini, E ; Toffart, AC ; Pérol, M ; Assié, JB ; Duruisseaux, M ; Coupez, D & al , Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients., Clin Lung Cancer, 2020, 21, e497-e510
- Torres-Lacomba, M ; Navarro-Brazález, B ; Prieto-Gómez, V ; Ferrandez, JC ; Bouchet, JY ; Romay-Barrero, H , Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial., Clin Rehabil, 2020, 34, 1230-1241
- Sternberg, CN ; Fizazi, K ; Saad, F ; Shore, ND ; De Giorgi, U ; Penson, DF & al , Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer., N Engl J Med, 2020, 382, 2197-2206
- Janoray, G ; Pointreau, Y ; Alfonsi, M ; Sire, C ; Geoffrois, L ; de Raucourt, D & al , Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial., Eur J Cancer, 2020, 133, 86-93
- Tao, Y ; Auperin, A ; Blanchard, P ; Alfonsi, M ; Sun, XS ; Rives, M & al , Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial., Radiother Oncol, 2020, 150, 18-25
- Fogliata, A ; Cayez, R ; Garcia, R ; Khamphan, C ; Reggiori, G ; Scorsetti, M & al , Technical Note: Flattening filter free beam from Halcyon linac: Evaluation of the profile parameters for quality assurance., Med Phys, 2020, 47, 3669-3674
- Pfisterer, J ; Shannon, CM ; Baumann, K ; Rau, J ; Harter, P ; Joly, F & al , Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial., Lancet Oncol, 2020, 21, 699-709
- François, E ; Mineur, L ; Deplanque, G ; Laplaige, P ; Smith, D ; Gourgou, S & al , Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (?75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study., Clin Colorectal Cancer, 2020, 19, e100-e109
- Pagès, F ; André, T ; Taieb, J ; Vernerey, D ; Henriques, J ; Borg, C & al , Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study., Ann Oncol, 2020, 31, 921-929
- Pfister, C ; Harter, V ; Allory, Y ; Radvanyi, F ; Culine, S , Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial., Contemp Clin Trials Commun, 2020, 17, 100536
- Palmieri, LJ ; Mineur, L ; Tougeron, D ; Rousseau, B ; Granger, V ; Gornet, JM & al , Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)., Oncologist, 2020, 25, e266-e275
- Debourdeau, P ; Cossou-Gbeto, C ; Takam-Sohwe, T ; Laroche, JP , [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?], Bull Cancer, 2020, 107, 224-233
- Mavaddat, N ; Antoniou, AC ; Mooij, TM ; Hooning, MJ ; Heemskerk-Gerritsen, BA ; Noguès, C & al , Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers., Breast Cancer Res, 2020, 22, 8
- Lievens, Y ; Defourny, N ; Corral, J ; Gasparotto, C ; Grau, C ; Borras, JM , How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement., Lancet Oncol, 2020, 21, e42-e54
- Randrian, V ; Adenis, A ; Desrame, J ; Barbier, E ; Di Fiore, F ; Lièvre, A & al , Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study., Dig Liver Dis, 2020, 52, 347-350
- Modi, S ; Saura, C ; Yamashita, T ; Park, YH ; Kim, SB ; Tamura, K & al , Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer., N Engl J Med, 2020, 382, 610-621
- Perez, T ; Montaleytang, M ; Boisseranc, C ; De Crozals, F ; Darbon, F ; Gérardin, E & al , [Feedback on clinical oncology pharmacy]., Ann Pharm Fr, 2020, 78, 70-75
- Penault-Llorca, F ; Kwiatkowski, F ; Arnaud, A ; Levy, C ; Leheurteur, M ; Uwer, L & al , Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14)., Breast, 2020, 49, 132-140
- Golemi, I ; Cote, L ; Iftikhar, O ; Brenner, B ; Tafur, A ; Bikdeli, B & al , Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry., J Vasc Surg Venous Lymphat Disord, 2020, 8, 353-359.e1
- Cutuli, B ; Lemanski, C ; De Lafontan, B ; Chauvet, MP ; De Lara, CT ; Mege, A & al , Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients., Clin Breast Cancer, 2020, 20, e164-e172
- Hammel, P ; Fabienne, P ; Mineur, L ; Metges, JP ; Andre, T ; De La Fouchardiere, C & al , Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial., Eur J Cancer, 2020, 124, 91-101
- Sada, PR ; López-Núñez, JJ ; Samperiz, A ; Soto, MJ ; Pedrajas, JM ; Porras, JA & al , Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry., Angiology, 2020, 71, 131-138
- Avnery, O ; Martin, M ; Bura-Riviere, A ; Barillari, G ; Mazzolai, L ; Mahé, I & al , D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry., J Intern Med, 2020, 287, 32-41
- Debourdeau, P ; Arvers, P ; Hij, A ; Bennani, H ; Desauw, C ; Falvo, N & al , Factors influencing patient »s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study., Support Care Cancer, 2020, 28, 287-293
- Jara-Palomares, L ; Alfonso, M ; Maestre, A ; Jimenez, D ; Garcia-Bragado, F ; Font, C & al , Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years., Sci Rep, 2019, 9, 20064
- Kaboré, EG ; Guenancia, C ; Vaz-Luis, I ; Di Meglio, A ; Pistilli, B ; Coutant, C & al , Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study., PLoS Med, 2019, 16, e1002989
- Ray-Coquard, I ; Pautier, P ; Pignata, S ; Pérol, D ; González-Martín, A ; Berger, R & al , Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer., N Engl J Med, 2019, 381, 2416-2428
- Alexia, C ; Cren, M ; Louis-Plence, P ; Vo, DN ; El Ahmadi, Y ; Dufourcq-Lopez, E & al , Polyoxidonium ® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer., Front Immunol, 2019, 10, 2693
- Figlioli, G ; Bogliolo, M ; Catucci, I ; Caleca, L ; Lasheras, SV ; Pujol, R & al , The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer., NPJ Breast Cancer, 2019, 5, 38
- D » »Hondt, V ; Canon, JL ; Roca, L ; Levy, C ; Pierga, JY ; Le Du, F & al , UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup., Eur J Cancer, 2019, 122, 91-100
- Lefèvre, JH ; Mineur, L ; Cachanado, M ; Denost, Q ; Rouanet, P ; de Chaisemartin, C & al , Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years » Follow-up Results of the Greccar-6 Randomized Multicenter Trial., Ann Surg, 2019, 270, 747-754
- Gensanne, D ; Hadj Henni, A ; Lauzin, Y ; Clarisse, P ; Thureau, S , [Inter- and intrafraction imaging during stereotactic body radiation therapy: Which solutions for which tumours?], Cancer Radiother, 2019, 23, 891-895
- Ferreira, AR ; Di Meglio, A ; Pistilli, B ; Gbenou, AS ; El-Mouhebb, M ; Dauchy, S & al , Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis., Ann Oncol, 2019, 30, 1784-1795
- Paz-Ares, L ; Dvorkin, M ; Chen, Y ; Reinmuth, N ; Hotta, K ; Trukhin, D & al , Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial., Lancet, 2019, 394, 1929-1939
- Badey, A ; Barateau, A ; Delaby, N ; Fau, P ; Garcia, R ; De Crevoisier, R & al , [Overview of adaptive radiotherapy in 2019: From implementation to clinical use]., Cancer Radiother, 2019, 23, 581-591
- Schmid, P ; Zaiss, M ; Harper-Wynne, C ; Ferreira, M ; Dubey, S ; Chan, S & al , Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial., JAMA Oncol, 2019, ,
- Riera-Mestre, A ; Mora-Luján, JM ; Trujillo-Santos, J ; Del Toro, J ; Nieto, JA ; Pedrajas, JM & al , Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry., Orphanet J Rare Dis, 2019, 14, 196
- Garrel, R ; Mazel, M ; Perriard, F ; Vinches, M ; Cayrefourcq, L ; Guigay, J & al , Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study., Clin Chem, 2019, 65, 1267-1275
- Broudic-Guibert, M ; Blay, JY ; Vazquez, L ; Evrard, A ; Karanian, M ; Taïeb, S & al , Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report., J Med Case Rep, 2019, 13, 245
- Charton, E ; Bachet, JB ; Hammel, P ; Desramé, J ; Chibaudel, B ; Cohen, R & al , Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial., Cancer Med, 2019, 8, 5079-5088
- Köhne, CH ; Karthaus, M ; Mineur, L ; Thaler, J ; Van den Eynde, M ; Gallego, J & al , Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab., Drugs R D, 2019, 19, 267-275
- Vieillevigne, L ; Khamphan, C ; Saez, J ; Hernandez, V , On the need for tuning the dosimetric leaf gap for stereotactic treatment plans in the Eclipse treatment planning system., J Appl Clin Med Phys, 2019, 20, 68-77
- Rossi, JF ; Céballos, P ; Lu, ZY , Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells., Cancer Commun (Lond), 2019, 39, 34
- Pivot, X ; Romieu, G ; Debled, M ; Pierga, JY ; Kerbrat, P ; Bachelot, T & al , 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial., Lancet, 2019, 393, 2591-2598
- Bidard, FC ; Kiavue, N ; Ychou, M ; Cabel, L ; Stern, MH ; Madic, J & al , Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial., Cells, 2019, 8,
- André, F ; Ciruelos, E ; Rubovszky, G ; Campone, M ; Loibl, S ; Rugo, HS & al , Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer., N Engl J Med, 2019, 380, 1929-1940
- Debourdeau, P ; Simonin, C ; Carbasse, C ; Debourdeau, T ; Zammit, C ; Scotté, F , [Primary prophylaxis of venous thromboembolism in ambulatory cancer patients treated with antineoplastic agents]., Rev Med Interne, 2019, 40, 523-532
- Joly, F ; Ahmed-Lecheheb, D ; Kalbacher, E ; Heutte, N ; Clarisse, B ; Grellard, JM & al , Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study., Ann Oncol, 2019, 30, 845-852
- Le Louedec, F ; Alix-Panabières, C ; Lafont, T ; Allal, BC ; Garrel, R ; Digue, L & al , Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients., Br J Clin Pharmacol, 2019, 85, 1357-1366
- Khorana, AA ; Soff, GA ; Kakkar, AK ; Vadhan-Raj, S ; Riess, H ; Wun, T & al , Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer., N Engl J Med, 2019, 380, 720-728
- Fuchs, CS ; Shitara, K ; Di Bartolomeo, M ; Lonardi, S ; Al-Batran, SE ; Van Cutsem, E & al , Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial., Lancet Oncol, 2019, 20, 420-435
- Boegemann, M ; Khaksar, S ; Bera, G ; Birtle, A ; Dopchie, C ; Dourthe, LM & al , Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study., BMC Cancer, 2019, 19, 60
- von Minckwitz, G ; Huang, CS ; Mano, MS ; Loibl, S ; Mamounas, EP ; Untch, M & al , Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer., N Engl J Med, 2019, 380, 617-628
- Bennouna, J ; André, T ; Campion, L ; Hiret, S ; Miglianico, L ; Mineur, L & al , Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial., Clin Colorectal Cancer, 2019, 18, e69-e73
- Christodoulou, M ; Blackhall, F ; Mistry, H ; Leylek, A ; Knegjens, J ; Remouchamps, V & al , Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial., J Thorac Oncol, 2019, 14, 63-71
- Touchefeu, Y ; Guimbaud, R ; Louvet, C ; Dahan, L ; Samalin, E ; Barbier, E & al , Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial., Gastric Cancer, 2019, 22, 577-586
- Girard, E ; Eon-Marchais, S ; Olaso, R ; Renault, AL ; Damiola, F ; Dondon, MG & al , Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing., Int J Cancer, 2019, 144, 1962-1974
- Hernandez, V ; Vera-Sánchez, JA ; Vieillevigne, L ; Khamphan, C ; Saez, J , A new method for modelling the tongue-and-groove in treatment planning systems., Phys Med Biol, 2018, 63, 245005
- Lazarescu, I ; Dubray, B ; Joulakian, MB ; Blanchard, P ; Chauvet, B ; Mahé, MA & al , Prevalence of burnout, depression and job satisfaction among French senior and resident radiation oncologists., Cancer Radiother, 2018, 22, 784-789
- Gravis, G ; Billon, E ; Baldini, C ; Massard, C ; Hilgers, W ; Delva, R & al , Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen., Eur J Cancer, 2018, 104, 236-238
- Cottu, P ; D » »Hondt, V ; Dureau, S ; Lerebours, F ; Desmoulins, I ; Heudel, PE & al , Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer., Ann Oncol, 2018, 29, 2334-2340
- Antonia, SJ ; Villegas, A ; Daniel, D ; Vicente, D ; Murakami, S ; Hui, R & al , Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC., N Engl J Med, 2018, 379, 2342-2350
- Michenot, N ; Rostaing, S ; Baron, L ; Faure, S ; Jovenin, N ; Hubault, P & al , [Opioid switch and change of route of administration in cancer patients treated by morphine]., Bull Cancer, 2018, 105, 1052-1073
- Weinberg, I ; Giri, J ; Kolluri, R ; Arcelus, JI ; Falgá, C ; Soler, S & al , Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry., J Thromb Thrombolysis, 2018, 46, 551-558
- van Rhee, F ; Voorhees, P ; Dispenzieri, A ; Fosså, A ; Srkalovic, G ; Ide, M & al , International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease., Blood, 2018, 132, 2115-2124
- Fogelman, D ; Cubillo, A ; García-Alfonso, P ; Mirón, MLL ; Nemunaitis, J ; Flora, D & al , Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer., Cancer Med, 2018, 7, 5382-5393
- Ninot, G ; Debourdeau, P ; Blanc-Legier, F ; De Crozals, F ; De Rauglaudre, G ; Khouri, S & al , [Supportive care for survivors]., Bull Cancer, 2018, 105, 763-770
- Bennouna, J ; Barlesi, F ; Do, P ; Dumont, P ; Cadranel, J ; Debieuvre, D & al , Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)., ESMO Open, 2018, 3, e000394
- de Crevoisier, R ; Bayar, MA ; Pommier, P ; Muracciole, X ; Pêne, F ; Dudouet, P & al , Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial., Int J Radiat Oncol Biol Phys, 2018, 102, 1420-1429
- Geoffrois, L ; Martin, L ; De Raucourt, D ; Sun, XS ; Tao, Y ; Maingon, P & al , Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial., J Clin Oncol, 2018, , JCO2017762591
- Frère, C ; Bournet, B ; Benzidia, I ; Jamelot, M ; Debourdeau, P ; Hij, A & al , [Venous thromboembolism and pancreatic cancer]., J Med Vasc, 2018, 43, 246-254
- Tao, Y ; Auperin, A ; Sire, C ; Martin, L ; Khoury, C ; Maingon, P & al , Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial., J Clin Oncol, 2018, , JCO2017762518
- Locher, C ; Pourel, N ; Le Caer, H ; Berard, H ; Auliac, JB ; Monnet, I & al , Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06)., Lung Cancer, 2018, 121, 25-29
- Coussirou, J ; Debourdeau, A ; Stancu, A ; Jean, C ; Azouza, W ; Chanet, B & al , Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study., Support Care Cancer, 2018, 26, 3827-3834
- Aparicio, T ; Bouché, O ; Francois, E ; Retornaz, F ; Barbier, E ; Taieb, J & al , Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer., Eur J Cancer, 2018, 97, 16-24
- Aparicio, T ; Bouché, O ; Taieb, J ; Maillard, E ; Kirscher, S ; Etienne, PL & al , Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results., Ann Oncol, 2018, 29, 2270
- André, T ; Vernerey, D ; Mineur, L ; Bennouna, J ; Desrame, J ; Faroux, R & al , Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial., J Clin Oncol, 2018, 36, 1469-1477
- Chaikh, A ; Ojala, J ; Khamphan, C ; Garcia, R ; Giraud, JY ; Thariat, J & al , Dosimetrical and radiobiological approach to manage the dosimetric shift in the transition of dose calculation algorithm in radiation oncology: how to improve high quality treatment and avoid unexpected outcomes?, Radiat Oncol, 2018, 13, 60
- Frikha, M ; Auperin, A ; Tao, Y ; Elloumi, F ; Toumi, N ; Blanchard, P & al , A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)., Ann Oncol, 2018, 29, 731-736
- Aparicio, T ; Bouché, O ; Taieb, J ; Maillard, E ; Kirscher, S ; Etienne, PL & al , Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results., Ann Oncol, 2018, 29, 133-138
Contact
Tél. : 04 90 27 61 61
Médecin de recherche clinique
Dr Rania BOUSTANY
Cadre de recherche clinique
Mme Armelle ROLLET
Mme Céleste DAVID
Infirmière de l’Unité de Recherche Clinique
Tél. : 04 90 27 62 12
Essais en cours
Base des essais
Registre des essais
Répertoire Régional
Un répertoire régional regroupant l’ensemble des essais en cancérologie ouverts dans les établissements de santé de Paca, de Corse et en Principauté de Monaco est également disponible sur le site d’ONCOPACA Corse.
Sa particularité est d’avoir été élaboré et être régulièrement mis à jour en coopération directe avec les promoteurs des essais
Sainte Catherine
